AIM ImmunoTech announced that the Netherlands Patent Office has granted a utility patent covering rugged dsRNA, a double-stranded RNA product related to Ampligen, which claims cover, among other aspects, compositions and compositions for use in the prevention or treatment of COVID-19. The new patent broadens AIM‘s existing portfolio for COVID-19 treatments to include rugged dsRNA. Ampligen is AIM’s RNA product candidate designed to modulate the immune system. Data from in vitro, pre-clinical and clinical experiments strongly suggest that Ampligen has a broad-spectrum early-onset antiviral effect by stimulating a powerful innate immune response. The Company has conducted experiments in SARS-CoV-2 showing Ampligen has a powerful impact on viral replication.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AIM:
- AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
- Biotech Alert: Searches spiking for these stocks today
- AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
- AIM ImmunoTech appoints Christopher McAleer as scientific officer
- AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
